Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphismsCitation formats

  • External authors:
  • R. L. Smith
  • E. Campalani
  • C. H. Smith
  • J. N W N Barker

Standard

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. / Warren, R. B.; Smith, R. L.; Campalani, E.; Eyre, S.; Smith, C. H.; Barker, J. N W N; Worthington, J.; Griffiths, C. E M.

In: British Journal of Dermatology, Vol. 160, No. 2, 02.2009, p. 438-441.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JNWN et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. British Journal of Dermatology. 2009 Feb;160(2):438-441. https://doi.org/10.1111/j.1365-2133.2008.08898.x

Author

Warren, R. B. ; Smith, R. L. ; Campalani, E. ; Eyre, S. ; Smith, C. H. ; Barker, J. N W N ; Worthington, J. ; Griffiths, C. E M. / Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. In: British Journal of Dermatology. 2009 ; Vol. 160, No. 2. pp. 438-441.

Bibtex

@article{94e1ce122b7f40c492fabc35de51f77e,
title = "Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms",
abstract = "Background: The use of methotrexate is limited by interindividual variability in response. Previous studies in patients with either rheumatoid arthritis or psoriasis suggest that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the drug. Objectives: To assess if single nucleotide polymorphisms (SNPs) across four genes that are relevant to methotrexate metabolism [folypolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH), methylenetetrahydrofolate reductase (MTHFR) and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC)] are related to treatment outcomes in patients with psoriasis. Methods: DNA was collected from 374 patients with psoriasis who had been treated with methotrexate. Data were available on individual outcomes to therapy, namely efficacy and toxicity. Haplotype-tagging SNPs (r2 > 0.8) for the four genes with a minor allele frequency of > 5% were selected from the HAPMAP phase II data. Genotyping was undertaken using the MassARRAY spectrometric method (Sequenom{\textregistered}). Results: There were no significant associations detected between clinical outcomes in patients with psoriasis treated with methotrexate and SNPs in the four genes investigated. Conclusions: Genetic variation in four key genes relevant to the intracellular metabolism of methotrexate does not appear to predict response to methotrexate therapy in patients with psoriasis. {\textcopyright} 2008 The Authors.",
keywords = "Methotrexate, Pharmacogenetics, Psoriasis",
author = "Warren, {R. B.} and Smith, {R. L.} and E. Campalani and S. Eyre and Smith, {C. H.} and Barker, {J. N W N} and J. Worthington and Griffiths, {C. E M}",
year = "2009",
month = feb,
doi = "10.1111/j.1365-2133.2008.08898.x",
language = "English",
volume = "160",
pages = "438--441",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "John Wiley & Sons Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms

AU - Warren, R. B.

AU - Smith, R. L.

AU - Campalani, E.

AU - Eyre, S.

AU - Smith, C. H.

AU - Barker, J. N W N

AU - Worthington, J.

AU - Griffiths, C. E M

PY - 2009/2

Y1 - 2009/2

N2 - Background: The use of methotrexate is limited by interindividual variability in response. Previous studies in patients with either rheumatoid arthritis or psoriasis suggest that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the drug. Objectives: To assess if single nucleotide polymorphisms (SNPs) across four genes that are relevant to methotrexate metabolism [folypolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH), methylenetetrahydrofolate reductase (MTHFR) and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC)] are related to treatment outcomes in patients with psoriasis. Methods: DNA was collected from 374 patients with psoriasis who had been treated with methotrexate. Data were available on individual outcomes to therapy, namely efficacy and toxicity. Haplotype-tagging SNPs (r2 > 0.8) for the four genes with a minor allele frequency of > 5% were selected from the HAPMAP phase II data. Genotyping was undertaken using the MassARRAY spectrometric method (Sequenom®). Results: There were no significant associations detected between clinical outcomes in patients with psoriasis treated with methotrexate and SNPs in the four genes investigated. Conclusions: Genetic variation in four key genes relevant to the intracellular metabolism of methotrexate does not appear to predict response to methotrexate therapy in patients with psoriasis. © 2008 The Authors.

AB - Background: The use of methotrexate is limited by interindividual variability in response. Previous studies in patients with either rheumatoid arthritis or psoriasis suggest that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the drug. Objectives: To assess if single nucleotide polymorphisms (SNPs) across four genes that are relevant to methotrexate metabolism [folypolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH), methylenetetrahydrofolate reductase (MTHFR) and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC)] are related to treatment outcomes in patients with psoriasis. Methods: DNA was collected from 374 patients with psoriasis who had been treated with methotrexate. Data were available on individual outcomes to therapy, namely efficacy and toxicity. Haplotype-tagging SNPs (r2 > 0.8) for the four genes with a minor allele frequency of > 5% were selected from the HAPMAP phase II data. Genotyping was undertaken using the MassARRAY spectrometric method (Sequenom®). Results: There were no significant associations detected between clinical outcomes in patients with psoriasis treated with methotrexate and SNPs in the four genes investigated. Conclusions: Genetic variation in four key genes relevant to the intracellular metabolism of methotrexate does not appear to predict response to methotrexate therapy in patients with psoriasis. © 2008 The Authors.

KW - Methotrexate

KW - Pharmacogenetics

KW - Psoriasis

U2 - 10.1111/j.1365-2133.2008.08898.x

DO - 10.1111/j.1365-2133.2008.08898.x

M3 - Article

C2 - 19016697

VL - 160

SP - 438

EP - 441

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -